Thursday 5th July 2018 |
Text too small? |
A2 Milk Co's new managing director and chief executive Jayne Hrdlicka will start on July 16, replacing Geoff Babidge who had been in the role since 2010.
Babidge announced his plans to retire last year, having overseen the company while its shares jumped from around $1 at the end of 2015 to a then-record of $8.75 on the back of successive strong sales as the company's infant formula attracted strong demand in China. The shares last closed at $11.40, and have gained 41 percent this year.
Hrdlicka was chief executive of Qantas Airways' Jetstar Group for the past five years and a non-executive director of Woolworths. Earlier in her career, she was a partner at Bain & Co in the US. When her appointment was announced in December, A2 chair David Hearn said she would focus on supporting the company's growth strategy across a broader nutritional products platform in established and new markets.
Under the terms of employment released to NZX, Hrdlicka will be paid A$1.5 million per year, reviewed annually, with a yearly bonus of up to 100 percent of her salary based on performance against key indicators, though the A2 board can also increase or decrease that by 20 percent on its own assessment of her performance.
Hrdlicka also gets rights to acquire A2 shares based on performance, worth up to 1.75 times her total fixed pay in the first year or A$2.625 million. In following years, she will be offered performance rights of 150 percent of her fixed pay. The first performance rights will vest when A2 achieves a certain annual growth rate in its diluted earnings per share, yet to be determined by the board.
In exchange for the short and long-term incentives she gave up by leaving Jetstar, A2 is paying Hrdlicka A$586,666 and giving her time-based rights for just under 600,000 A2 shares to vest between August this year and August 2019. Those rights aren't subject to performance hurdles.
(BusinessDesk)
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors